Survodutide 10mg Dosage & Mixing Guide

What is Survodutide?

Survodutide (also known as BI 456906) is a GLP-1 receptor and glucagon receptor dual agonist developed by Boehringer Ingelheim and Zealand Pharma for research into obesity and metabolic dysfunction-associated steatohepatitis (MASH).

The peptide works by co-activating two distinct receptor pathways. Through the GLP-1 receptor it influences appetite, satiety, and insulin secretion, while through the glucagon receptor it is studied for its effects on energy expenditure and hepatic fat metabolism. This dual mechanism has made it a subject of investigation for both weight management and liver (MASH) endpoints.

Survodutide has a pharmacokinetic profile that supports once-weekly administration in research protocols. It is a research peptide and is not an approved medicine.

Quick Reference

Reconstitution Guide

Materials Needed

• Survodutide 10mg lyophilized vial
• Bacteriostatic water (BAC water)
• Insulin syringes (U-100, 29-31 gauge)
• Alcohol swabs
• Sharps container

Step-by-Step Instructions

1. Prepare your workspace — Clean your work area and gather all materials. Wash hands thoroughly.

2. Clean the vial stoppers — Wipe the Survodutide vial stopper and BAC water vial with alcohol swabs. Allow to dry completely.

3. Draw the BAC water — Using a sterile syringe, draw 2mL of bacteriostatic water.

4. Add water to peptide vial — Insert the needle into the Survodutide vial and slowly inject the BAC water down the inside wall of the vial. Do not spray directly onto the powder.

5. Allow to dissolve — Survodutide may take 5-10 minutes to fully dissolve. Gently swirl occasionally — never shake vigorously.

6. Verify dissolution — The solution should be completely clear and colorless. If cloudy or particles remain, continue gentle swirling.

7. Label and store — Write the reconstitution date on the vial. Store in refrigerator immediately.

Dosage Protocol

Concentration Calculations

With 10mg peptide in 2mL BAC water:

• Concentration: 5mg/mL = 5000mcg/mL
• Per unit (U-100 syringe): 50mcg per unit

Common Dose Calculations

Suggested Titration Protocol

Survodutide research protocols typically employ gradual dose escalation to assess tolerance:

Important Notes:

• Each dose level should be maintained for at least 4 weeks before escalation
• Not all research protocols require reaching maximum dose
• Dose escalation should be based on research objectives and tolerance

Injection Guide

Subcutaneous Administration

1. Clean the injection site with an alcohol swab
2. Pinch a fold of skin (abdomen, thigh, or upper arm)
3. Insert needle at 90° angle for most body types
4. Inject slowly and steadily
5. Wait 5-10 seconds before withdrawing needle
6. Apply light pressure if needed — do not rub

Site Rotation

Rotate between these areas weekly:

• Abdomen (2+ inches from navel) — most common
• Outer thigh (front/outer area)
• Back of upper arm

Consistency tip: Administer on the same day each week to maintain steady levels.

Storage Requirements

Lyophilized (Powder Form)

• Temperature: -20°C (-4°F) or colder
• Duration: 2+ years
• Conditions: Protect from light and moisture

Reconstituted (Mixed with BAC Water)

• Temperature: 2-8°C (36-46°F) — standard refrigerator
• Duration: 4-6 weeks
• Conditions: Keep away from light, never freeze reconstituted solution

Important Storage Notes

• Survodutide is sensitive to temperature — minimize time outside refrigeration
• Do not use if solution becomes cloudy, discolored, or contains particles
• Keep track of reconstitution date and discard after 6 weeks maximum

Research Considerations

Mechanism of Action

Survodutide’s research applications stem from its dual GLP-1 and glucagon receptor agonism:

• GLP-1 receptor effects: Appetite and satiety signaling, glucose-dependent insulin secretion
• Glucagon receptor effects: Energy expenditure, hepatic fat metabolism
• Metabolic: Studied for combined effects on body weight and liver endpoints
• Hepatic: Investigated in metabolic dysfunction-associated steatohepatitis (MASH) research

Key Research Findings

Phase 2 clinical trials have investigated:

• Effects on body weight in obesity research through dual receptor co-activation
• Improvement of liver histology endpoints in MASH research
• Dose-dependent responses across a gradual titration range

Safety & Handling

General Precautions

• Use sterile technique for all preparations
• Never reuse needles or syringes
• Dispose of sharps properly in designated containers
• Store away from children and unauthorized persons

Research Considerations

• Survodutide is for research purposes only
• Survodutide is an investigational compound and is not an approved medicine
• Research-grade peptides are not equivalent to pharmaceutical preparations
• Follow institutional guidelines for peptide research

Sourcing for Research

Source from verified suppliers that provide third-party testing and certificates of analysis (COA) for each batch. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.

Scientific References

1. le Roux CW, et al. “Survodutide (BI 456906), a glucagon/GLP-1 receptor dual agonist, for the treatment of obesity: a randomised, double-blind, placebo-controlled, phase 2 dose-finding trial.” 2024.
2. Sanyal AJ, et al. “Survodutide in metabolic dysfunction-associated steatohepatitis (MASH): a phase 2 trial.” New England Journal of Medicine. 2024.

Last updated: July 04, 2026

Disclaimer: This information is for educational and research purposes only. Survodutide as a research peptide is not intended for human consumption. Survodutide is an investigational compound and is not an approved medicine. Always follow applicable laws and institutional guidelines.